CNTA

Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors

Retrieved on: 
Thursday, January 26, 2023
Food, Tumor microenvironment, IND, CNTA, Cancer, Patient, Clinical trial, TME, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, CD47, Toxicity, Pharmaceutical industry

LB101, a conditionally tetravalent PD-L1xCD47 LockBody® bispecific monoclonal antibody targeting solid tumors, is the first product candidate developed using the Company’s proprietary LockBody technology which is designed to selectively drive potent effector function activity, such as CD47, in the tumor microenvironment (TME) while avoiding systemic toxicity.

Key Points: 
  • LB101, a conditionally tetravalent PD-L1xCD47 LockBody® bispecific monoclonal antibody targeting solid tumors, is the first product candidate developed using the Company’s proprietary LockBody technology which is designed to selectively drive potent effector function activity, such as CD47, in the tumor microenvironment (TME) while avoiding systemic toxicity.
  • "We are very excited to be bringing our first LockBody candidate to the clinic and to be advancing a potentially transformative technology for patients with solid tumors,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
  • “The clearance of our IND for LB101 is an important milestone for our company as we have an ambitious strategy to advance multiple potential LockBody candidates in areas where there is a significant need for new cancer treatment options.
  • We look forward to initiating the Phase 1/2a trial of LB101 as soon as possible.”

Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson

Retrieved on: 
Wednesday, November 30, 2022
Culture, Alnylam Pharmaceuticals, Patient, Human, CNTA, Commercial, Pfizer, Pharmaceutical industry, Management

BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer.

Key Points: 
  • BOSTON and LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company focused on discovering and developing medicines that are transformational for patients, today announced Karen Anderson as its new Chief People Officer.
  • Karen joins Centessa with over 25 years of experience in human resources roles spanning the biotechnology/pharmaceutical, technology and healthcare industries.
  • Prior to joining Centessa, Karen was Chief Human Resources Officer at Mimecast Limited.
  • Centessa attracts the industrys best and brightest people, said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, November 28, 2022
Observation, Restaurant, DoorDash, Tripura Merger Agreement, A1AT, Bloomberg, Risk, Autosome, Class Action, Defendant, Class, Registration statement, BID, ADS, PayPal, P.C, Farm, NNA, Patient, Prospectus, Register, CNTA, SCH, Churn, PYPL, Growth, Polycystic kidney disease, DNA, Partnership, News, NYSE, Form, Fraud, Initial, Liver, Acquisition, AATD, Complaint, IPO, AE, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Opendoor, Subway, Algorithm, Mergers and acquisitions

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate

Retrieved on: 
Monday, November 28, 2022
Class Action Lawsuit, Professional Services, Legal, American depositary receipt, Class, Defendant, Court, CNTA, Person, Security (finance), Risk management

Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/cnta .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firms site: www.bgandg.com/cnta .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • If you suffered a loss in Centessa you have until November 28, 2022 to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Centessa Pharmaceuticals plc - CNTA

Retrieved on: 
Thursday, November 24, 2022
CNTA, Security (finance), Insurance, Risk management

Shareholders have until November 28, 2022 to file lead plaintiff applications in the securities class action lawsuit.

Key Points: 
  • Shareholders have until November 28, 2022 to file lead plaintiff applications in the securities class action lawsuit.
  • Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.
  • The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
  • Prior results do not guarantee similar outcomes.

CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA

Retrieved on: 
Wednesday, November 23, 2022
FREE, Register, Lawyer, CNTA, Prospectus, District court, Security (finance)

This action is pending in the United States District Court for the Southern District of New York.

Key Points: 
  • This action is pending in the United States District Court for the Southern District of New York.
  • Centessa investors should visit us at https://claimsfiler.com/cases/nasdaq-cnta/ or call toll-free (844) 367-9658.
  • The case is Fernandes v. Centessa Pharmaceuticals Plc, et al., No.
  • ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements.

CENTESSA PHARMACEUTICALS PLC (NASDAQ: CNTA) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Centessa Pharmaceuticals plc (NASDAQ: CNTA)

Retrieved on: 
Tuesday, November 22, 2022
Observation, Central District, AATD, A1AT, Polycystic kidney disease, DNA, American depositary receipt, Labour government, Autosome, Patient, IPO, Defendant, Prospectus, Court, Registration statement, The Legal 500, Register, CNTA, AE, Investment, District court, News, BID, ADS, Form, Advertising, Liver, Pharmaceutical industry, Security (finance)

NEW YORK, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or otherwise acquired: (a) Centessa Pharmaceuticals plc (“Centessa” or the “Company”) (NASDAQ: CNTA) American Depositary Shares (“ADSs”) pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about May 28, 2021 (the “IPO” or “Offering”); and/or (b) Centessa securities between May 28, 2021 and June 1, 2022, both dates inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Central District of California and alleges violations of the Securities Act of 1933 and Securities Exchange Act of 1934.

Key Points: 
  • If so, please visit Centessa Pharmaceuticals plc Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.
  • Centessa is a clinical-stage pharmaceutical company that purports to discover, develop, and deliver medicines to patients.
  • Plaintiff alleges that Defendants made materially false and misleading statements in the Offering Documents and throughout the Class Period.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, November 22, 2022
Observation, Restaurant, DoorDash, Tripura Merger Agreement, A1AT, Bloomberg, Risk, Autosome, Class Action, Defendant, Class, Registration statement, BID, ADS, PayPal, P.C, Farm, NNA, Patient, Prospectus, Register, CNTA, SCH, Churn, PYPL, Growth, Polycystic kidney disease, DNA, Partnership, News, NYSE, Form, Fraud, Initial, Liver, Acquisition, AATD, Complaint, IPO, AE, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Opendoor, Subway, Algorithm, Mergers and acquisitions

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Centessa Pharmaceuticals plc of Class Action Lawsuit and Upcoming Deadline – CNTA

Retrieved on: 
Thursday, November 17, 2022
Observation, AATD, LLP, A1AT, Polycystic kidney disease, DNA, American depositary receipt, Pomerantz, Autosome, Patient, Person, Complaint, IPO, Prospectus, Court, Ext, Registration statement, Defendant, Register, CNTA, AE, District court, News, BID, Class, ADS, Form, Liver, Security (finance), Pharmaceutical industry, Animal

NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.

Key Points: 
  • NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Centessa Pharmaceuticals plc (Centessa or the Company) (NASDAQ: CNTA) and certain of its officers and directors.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, November 17, 2022
Observation, Restaurant, DoorDash, Tripura Merger Agreement, A1AT, Bloomberg, Risk, Autosome, Class Action, Defendant, Class, Registration statement, BID, ADS, PayPal, P.C, Farm, NNA, Patient, Prospectus, Register, CNTA, SCH, Churn, PYPL, Growth, Polycystic kidney disease, DNA, Partnership, News, NYSE, Form, Fraud, Initial, Liver, Acquisition, AATD, Complaint, IPO, AE, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Opendoor, Subway, Algorithm, Mergers and acquisitions

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.